Loading
SETBP1 (SET-binding protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Breast cancer and 5 more.
UniProt has no function text for Q9Y6X0; HGNC names it "SET binding protein 1".
CIViC holds 3 clinical evidence items and 0 assertions across 3 variants. Open Targets scores its association with cancer at 0.84 (direct and indirect evidence; datatypes literature 0.95, genetic association 0.83, somatic mutation 0.84, genetic literature 0.83). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Adrenocortical Carcinoma.
In plain words · SETBP1 (SET-binding protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Breast cancer and 5 more.
SETBP1 (SET-binding protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Breast cancer and 5 more.
UniProt has no function text for Q9Y6X0; HGNC names it "SET binding protein 1". Location: Nucleus (UniProt).
No product in this corpus aims at SETBP1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a fusion partner (UniProt records a translocation); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA SETBP1: RNA low tissue specificity; no normal tissue stained high; highest cancer staining carcinoid (1 of 4 high). Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms, Leukaemia, Breast cancer (all types), Adrenocortical carcinoma, Skin cancer (all types), Lung cancer (all types), Neuroendocrine tumours); Open Targets associates it with 4 specific cancer types at or above 0.5 (chronic myeloid leukemia, myelodysplastic syndrome, acute myeloid leukemia, breast carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q9Y6X0; CIViC gene SETBP1; IntOGen SETBP1; Human Protein Atlas SETBP1 tissue; Open Targets ENSG00000152217 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Ishikawa et al, DNA Res, 1997, "Prediction of the coding sequences of unidentified human genes. VIII. 78 new cDNA clones from brain which code for large proteins in vitro". Source.
Sources: HGNC HGNC:15573 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9Y6X0 (protein name, function text, keywords and locations (REST API)); CIViC gene SETBP1 (3 evidence items, 0 assertions, 3 variants; diseases: Chronic Myeloid Leukaemia, Juvenile Myelomonocytic Leukaemia, Atypical Chronic Myeloid Leukaemia, BCR-ABL1 Negative (GraphQL API, CC0)); Open Targets ENSG00000152217 (association with cancer (MONDO_0004992) 0.84; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.51, gastric cancer 0.51, melanoma 0.57, neuroendocrine neoplasm 0.52, acute myeloid leukaemia 0.67, skin cancer 0.57 (GraphQL API, CC0)); IntOGen SETBP1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
UniProt has no function text for Q9Y6X0; HGNC names it "SET binding protein 1". Location: Nucleus (UniProt). Locus 18q12.3 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
No normal tissue stained high.
Medium only: breast cancer, cervical cancer, colorectal cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SETBP1" OR ABSTRACT:"SETBP1" OR TITLE:"SET binding protein 1" OR ABSTRACT:"SET binding protein 1" OR TITLE:"SET-binding protein" OR ABSTRACT:"SET-binding protein" OR TITLE:"KIAA0437" OR ABSTRACT:"KIAA0437") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SETBP1, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), Lung cancer (all types).
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), IntOGen.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), IntOGen.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types).
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC.